Thank you for your interest in the whitepaper:
Winning at Your Drug Development Strategy: A Playbook for Emerging Biotechs
Learn More About Why Medpace is Trusted by Biotech™
Innovative, emerging biotechs are driving the drug development pipeline, yet must enact strategies to accelerate clinical development within their competitive landscape. Due to our understanding of the unique challenges emerging biotechs face, our culture and our operating structure are purposely designed to accommodate efficient partnering, important for emerging biotechs with limited resources and limited experience.
2022 marks the year in which we celebrate 30 years of being Trusted by Biotech™, as we’ve been partnering with biopharma companies since our inception in 1992. We draw on our experience to create the best team and solution for you because at Medpace we share the same commitment to your compound that you do.
Medpace at a Glance:
- Top 10 CRO
- 90% of our clients are small to medium-sized biopharma companies
- 5,000+ employees in 40 countries
- 30 offices globally; strong presence in the United States, Europe, and Japan/Asia-Pac
- Submissions in over 60 countries
- 4 CAP-Accredited Central Labs
- Bioanalytical Lab (small and a large molecule)
- Core Imaging and ECG Core Lab
- Phase I Unit
- Renowned regulatory affairs (ATMP/gene – cell therapies/GMO)
- One-of-a-kind research campus
- Scientific reputation and relationships
- Organic growth and high stability
Contact us to connect with our internal experts.